Penumbra Inc (PEN) Stock Price & Analysis
Penumbra Inc (PEN) rose 0.31% to USD 321.06 as of June 10, 2026 at 00:39 UTC, according to Nexqual real-time market data.
PEN last closed at USD 320.07; the session ranged USD 320.4–322.09 on volume of 310,244 shares. Market capitalization is $12.63B, with a 52-week range of USD 221.26–362.41 (NYQ). Source: Nexqual, June 10, 2026 at 00:39 UTC.
Key Statistics (as of June 10, 2026 at 00:39 UTC)
| Price | USD 321.06 |
|---|---|
| Change | ▲ 0.31% (up) |
| Previous Close | USD 320.07 |
| Open | USD 320.77 |
| Day Range | USD 320.4 – 322.09 |
| 52-Week Range | USD 221.26 – 362.41 |
| Volume | 310,244 shares |
| Market Cap | $12.63B |
| Exchange | NYQ |
Technical Analysis (PEN)
Nexqual's technical model rates PEN "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:39 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.47 (neutral) |
| vs SMA50 | Below (USD 326.05) |
| MACD | -1.9 (negative) |
Analyst Ratings (PEN)
Wall Street analysts rate PEN "Hold" based on 14 analysts, with a mean price target of USD 363.36 (range USD 326–374), per Nexqual as of June 10, 2026 at 00:39 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 363.36 |
| High Target | USD 374 |
| Low Target | USD 326 |
| Buy / Hold / Sell | 4 / 13 / 0 |
Earnings (PEN)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 1.16 |
| Revenue Estimate | $390.83M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.01 vs est 1.06 ▼ miss |
| 2025-12-31 | USD 1.18 vs est 1.11 ▲ beat |
| 2025-09-30 | USD 0.97 vs est 0.92 ▲ beat |
| 2025-06-30 | USD 0.86 vs est 0.82 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
Financials & Fundamentals (PEN)
| Total Revenue | $1.45B |
|---|---|
| Revenue Growth (YoY) | +15.60% |
| Gross Margin | +67.38% |
| Operating Margin | +10.20% |
| Profit Margin | +11.76% |
| ROE | +12.73% |
| Debt / Equity | 14.67 |
| Current Ratio | 6.02 |
| Total Cash | $615.66M |
| Total Debt | $216.18M |
| Free Cash Flow | $141.80M |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
Financial Health Score (PEN)
Nexqual rates Penumbra Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:39 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 67%, operating 10% |
| Balance Sheet | Strong — $616M cash vs $216M debt, net cash position |
| Cash Flow | Solid — FCF $142M, 10% margin |
| Efficiency | Mixed — ROE 13%, ROA 6.7% |
Ownership (PEN)
| Insider Ownership | +2.90% |
|---|---|
| Institutional Ownership | +87.95% |
| Shares Outstanding | 39.33M |
| Float | 38.23M |
| Short % of Float | +5.60% |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
Leadership (PEN)
Penumbra Inc is led by Adam Elsesser (age 63), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 00:39 UTC.
| Co-Founder, Chairman & CEO | Adam Elsesser (age 63) |
|---|---|
| President | Shruthi Narayan (age 40) |
| Co-Founder & Director | Arani Bose (age 63) |
| Chief Financial Officer | Maggie S. Yuen (age 53) |
| Executive Vice President of Operations | Ben Sorci |
Major Backers & Investors (PEN)
Notable institutional backers of Penumbra Inc include HBK Investments L P, Millennium Management, Baillie Gifford, according to Nexqual as of June 10, 2026 at 00:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HBK Investments L P | 4.16% |
| Millennium Management | 2.79% |
| Baillie Gifford | 2.14% |
| Balyasny Asset Management LP | 1.94% |
| Goldman Sachs | 1.83% |
| SmallCap World Fund Inc | 1.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.33% |
| BlackRock | 15.02% |
| State Street | 3.76% |
| Geode Capital | 2.02% |
Source: Nexqual, June 10, 2026 at 00:39 UTC.
From Penumbra Inc's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- We developed our proprietary aspiration source as a fully-integrated system specifically for mechanical thrombectomy by vacuum aspiration.
- Penumbra System Reperfusion Catheters are the cornerstone of the Penumbra System and are manufactured using a variety of proprietary processes and materials science innovations for use in revascularization of patients with acute ischemic stroke.
- Intellectual Property Our success depends in part on our ability to protect our proprietary technology and intellectual property and operate without infringing the patents and other proprietary rights of third parties.
- In addition, FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality Management System Regulation ("QMSR").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PODD | Insulet Corporation | USD 159.61 | ▲ 4.17% |
| GKOS | Glaukos Corporation | USD 126.34 | ▲ 1.07% |
| IRTC | iRhythm Holdings, Inc. | USD 113.83 | ▲ 5.3% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| MASI | Masimo Corporation | USD 179.95 | ▲ 0.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:39 UTC. This page is informational and not investment advice.